POPART for Post-Prostatectomy Recurrence: Safety & Efficacy – ASTRO 2025
- A new study suggests adding a radiopharmaceutical to stereotactic body radiation therapy (SBRT) may significantly delay prostate cancer progression.
- Researchers at the University of California, San Francisco (UCSF) have found that combining SBRT with the radiopharmaceutical lutetium-177 PSMA (177Lu-PSMA) can extend the time it takes for prostate...
- Alpha particles, emitted by lutetium-177, have a short range, delivering a potent dose of radiation directly to cancer cells while sparing nearby healthy tissue.PSMA acts as a homing...
“`html
Radiopharmaceutical Boosts Stereotactic Radiation Therapy for Prostate Cancer
Table of Contents
A new study suggests adding a radiopharmaceutical to stereotactic body radiation therapy (SBRT) may significantly delay prostate cancer progression. The research, published in the *Journal of Clinical Oncology*, offers a promising avenue for men with high-risk localized prostate cancer.
What is the Breakthrough?
Researchers at the University of California, San Francisco (UCSF) have found that combining SBRT with the radiopharmaceutical lutetium-177 PSMA (177Lu-PSMA) can extend the time it takes for prostate cancer to progress, specifically in men whose cancer has spread locally but not to distant parts of the body. SBRT delivers high doses of radiation to a precise tumor location, while 177Lu-PSMA targets prostate-specific membrane antigen (PSMA), a protein found in high concentrations on prostate cancer cells. This combination aims to maximize cancer cell destruction while minimizing damage to surrounding healthy tissues.
How Does 177Lu-PSMA Work?
177Lu-PSMA is a targeted alpha therapy (TAT). Alpha particles, emitted by lutetium-177, have a short range, delivering a potent dose of radiation directly to cancer cells while sparing nearby healthy tissue.PSMA acts as a homing device, guiding the radiopharmaceutical specifically to prostate cancer cells. This targeted approach is particularly beneficial for cancers that have spread beyond the prostate gland but remain localized.
Study Details and findings
The Phase III trial, known as PSMA-LBT-001, involved 160 men with high-risk localized or locally advanced prostate cancer. Participants received either SBRT alone or SBRT plus 177Lu-PSMA. The study’s primary endpoint was the time to prostate-specific antigen (PSA) progression, a marker of cancer growth. Medical Xpress reports that the combination therapy significantly extended the time to PSA progression compared to SBRT alone (median 23.7 months vs. 10.8 months, hazard ratio 0.49). This translates to a nearly 50% reduction in the risk of cancer progression.
Secondary endpoints, including overall survival and distant metastasis-free survival, are still being monitored. Initial data suggest a trend towards improved outcomes in these areas as well, but longer follow-up is needed to confirm these findings.
| Treatment Group | Median Time to PSA Progression (Months) | Hazard Ratio (vs. SBRT Alone) |
|---|---|---|
| SBRT Alone | 10.8 | 1.0 |
| SBRT + 177Lu-PSMA | 23.7 | 0.49 |
side Effects and Safety
The combination therapy was generally well-tolerated. the most common side effects